Skip to main content
INMB
NASDAQ Life Sciences

INmune Bio Trims Q3 Loss to $4.7M, Sets Full UK Filing for February 2027

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.175
Mkt Cap
$32.611M
52W Low
$1.09
52W High
$2.6
52W Position info
7.8% above low
Off High info
55% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

INMB is trading near its 52-week low of $1.09 (7.8% above the low).

Summary

INmune Bio cut its Q3 2026 net loss to about $4.7 million from $6.5 million a year earlier, with R&D down to $3.2 million and G&A to $1.8 million. Cash stood at $16.3 million on September 30; adding the $4.5 million October stock-and-warrant sale, management says funding lasts through Q3 2027 — a company with a going-concern history now has runway past its key regulatory dates. The regulatory plan shifted: instead of a rolling review, INmune now plans a complete Ebstrocel MAA to the UK MHRA in early February 2027, with an agency response expected three to six months later and potential UK approval mid-2027. The US BLA is targeted for mid-2027 and is being prioritized ahead of an EMA filing, and the Uniphar named-patient access deal gives a possible pre-approval revenue path in Europe, the Middle East and North Africa. The February 2027 MAA submission is the next hard date; a slip there pushes the mid-2027 approval expectation.

At the time of this announcement, INMB was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.6M. The 52-week trading range was $1.09 to $2.60. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

INMB - Latest Insights

INMB
Oct 29, 2026, 7:30 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.819 info
Change: -$0.701 (-46%) info
Market Cap: $25.355M info
INMB
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.819 info
Change: -$0.591 (-42%) info
Market Cap: $25.355M info
INMB
Oct 21, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $0.819 info
Change: -$0.870 (-52%) info
Market Cap: $25.355M info
INMB
Oct 21, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.819 info
Change: -$0.811 (-50%) info
Market Cap: $25.355M info
INMB
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.03
Real-time Price: $0.819 info
Change: -$1.21 (-60%) info
Market Cap: $25.355M info